Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
暂无分享,去创建一个
K. Flaherty | A. Ribas | P. Moore | J. Wigginton | H. Burris | R. Cohen | J. Weber | B. Chmielowski | J. Powderly | D. Loo | E. Bonvini | J. Vasselli | R. Szmulewitz | G. Cote | J. Baughman | Francine Z Chen